
Monitoring and Managing CTLA-4 Toxicities in Squamous NSCLC
In this segment, the panel discusses monitoring and managing immune-related toxicities in patients with advanced squamous non-small cell lung cancer (NSCLC) receiving CTLA-4-directed therapy after prior immunotherapy.
Episodes in this series

In this segment, the panel discusses monitoring and managing immune-related toxicities in patients with advanced squamous non-small cell lung cancer (NSCLC) receiving CTLA-4-directed therapy after prior immunotherapy. Dr. Edward Kim emphasizes vigilance for a broad range of potential immune-related adverse events, including colitis, skin toxicities, thyroid dysfunction, hepatic abnormalities, and less specific symptoms that may signal other immune-mediated complications. The discussion highlights the importance of establishing multidisciplinary support for patients treated in community settings, where access to specialists experienced in managing these toxicities may be limited. Dr. Kim describes the use of structured clinical pathways, defined laboratory and reassessment schedules, emergency contacts, and telehealth connections with specialty teams to support community clinicians. Dr. Narjust Florez emphasizes patient and caregiver education, particularly for individuals who may live far from treatment centers or hesitate to report symptoms. The panel also discusses providing patients with treatment and safety information cards that identify the therapy, expected toxicities, and appropriate contacts to facilitate timely recognition and management across care settings.
Related to this article










